Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: - Is Lenti-HPV-07 safe? - Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type - either study drug group A: recurrent and/or metastatic cancer - or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06319963
Study type Interventional
Source Theravectys S.A.
Contact Daniel Loera
Phone 713-256-8202
Email dloera@oncobay.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date March 2024
Completion date December 2026

See also
  Status Clinical Trial Phase
Completed NCT02113878 - Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Phase 1
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Active, not recruiting NCT05524025 - The SPOT-HPV Study
Recruiting NCT05600842 - De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Recruiting NCT05973487 - A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors Phase 1
Terminated NCT05061940 - This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Recruiting NCT05119036 - Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma Phase 2
Recruiting NCT06088381 - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Phase 2
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2
Recruiting NCT05814549 - A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
Active, not recruiting NCT04260126 - Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC Phase 2
Recruiting NCT05108870 - TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers Phase 1/Phase 2
Recruiting NCT05307939 - A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) Phase 2
Active, not recruiting NCT04871490 - Improving Detection and Early Action for HPV-positive Oropharynx Cancer N/A
Terminated NCT03601507 - Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer Phase 2
Active, not recruiting NCT01855451 - Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma Phase 3
Terminated NCT04301011 - Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05639972 - E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers Phase 1/Phase 2
Active, not recruiting NCT03978689 - A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Phase 1